Mayo Clinic

July 28, 2021

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).

July 27, 2021

Complete resolution of the index T2-lesion and resolution of all T2 lesions occurred most often in patients with MOGAD rather than AQP4-IgG-NMOSD or MS.

July 20, 2021

Instead of a smooth-contoured, thin, and regular ring or arc typically seen, pattern 3 patients had atypical rings such as irregularly thick rings and arcs.

July 11, 2021

Total lesion volume and index lesion-related severity correlated with EDSS scores and cognitive performance, while volumetric cortical and subcortical gray matter correlated less strongly.

June 01, 2021

Identified by Mayo Clinic investigators, the protein-coding gene SERPINA5 was found to be associated with tau expression, characteristic of Alzheimer disease pathology.

May 28, 2021

The professor of neurology at Mayo Clinic detailed the next steps in understanding more about the impact social determinants of health have on epilepsy care.